In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of pancreatic cancer comprising a CDK inhibitor selected from the compounds of formula I and a compound capable of inhibiting epidermal growth factor receptor (EGFR) kinase activity. The present invention also provides a combination wherein said pharmaceutical combination useful for the treatment of pancreatic cancer further comprises gemcitabine. The present invention also provides a method for the treatment of pancreatic cancer in a subject comprising administering said pharmaceutical combination(s) to said subject.
